产品
编 号：F744604
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 1384260-65-4
产品详情
生物活性：
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.
体内研究：
Aducanumab (30 mg/kg，腹腔注射，单剂量) 在 22 个月大的 Tg2576 转基因小鼠中结合所有形态类型的脑 Aβ 斑块，包括弥漫性 Aβ 沉积和致密性 Aβ 斑块。Aducanumab (0.3-30 mg/kg, 腹腔注射, 每周一次, 6 个月) 在 9.5 到 15.5 个月大的 Tg2576 转基因小鼠中以剂量依赖性方式减少可溶性和不溶性 Aβ。Aducanumab (10 mg/kg, 腹腔注射, 每周, 6 个月) 可将 18 个月大的 Tg2576 小鼠的细胞内钙恢复至控制水平。Aducanumab (0.4-1 mg/mL, 脑室注射, 20 分钟) 在 Tg2576 小鼠中可导致淀粉样蛋白负荷快速减少，从而促进斑块清除。Animal Model:9.5- to 15.5-month-old Tg2576 transgenic mice
Dosage:0.3-30 mg/kg
Administration:Intraperitoneal injection (i.p.), weekly, 6 months
Result: Increased recruitment of Iba-1-positive microglia to Aβ plaques.
Animal Model:18-month-old Tg2576 mice
Dosage:10 mg/kg
Administration:Intraperitoneal injection (i.p.), weekly, 6 months
Result:Restored neurite baseline calcium to control levels.Decreased the number of neurites with elevated levels of calcium after 2 weeks.Decreased the percentage of cell bodies with calcium overload.Restored the levels of VILIP and SERCA to control levels.Increased the cell numbers of NR1 and NR2A.
Animal Model:22-month-old transgenic Tg2576 mice
Dosage:0.4-1 mg/mL
Administration:Intracerebroventricular injection (ICV), 20 min
Result:Decreased the number of amyloid plaque.Decreased the size of the remaining individual plaques.Reduced amyloid plaque burden.
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.
体内研究：
Aducanumab (30 mg/kg，腹腔注射，单剂量) 在 22 个月大的 Tg2576 转基因小鼠中结合所有形态类型的脑 Aβ 斑块，包括弥漫性 Aβ 沉积和致密性 Aβ 斑块。Aducanumab (0.3-30 mg/kg, 腹腔注射, 每周一次, 6 个月) 在 9.5 到 15.5 个月大的 Tg2576 转基因小鼠中以剂量依赖性方式减少可溶性和不溶性 Aβ。Aducanumab (10 mg/kg, 腹腔注射, 每周, 6 个月) 可将 18 个月大的 Tg2576 小鼠的细胞内钙恢复至控制水平。Aducanumab (0.4-1 mg/mL, 脑室注射, 20 分钟) 在 Tg2576 小鼠中可导致淀粉样蛋白负荷快速减少，从而促进斑块清除。Animal Model:9.5- to 15.5-month-old Tg2576 transgenic mice
Dosage:0.3-30 mg/kg
Administration:Intraperitoneal injection (i.p.), weekly, 6 months
Result: Increased recruitment of Iba-1-positive microglia to Aβ plaques.
Animal Model:18-month-old Tg2576 mice
Dosage:10 mg/kg
Administration:Intraperitoneal injection (i.p.), weekly, 6 months
Result:Restored neurite baseline calcium to control levels.Decreased the number of neurites with elevated levels of calcium after 2 weeks.Decreased the percentage of cell bodies with calcium overload.Restored the levels of VILIP and SERCA to control levels.Increased the cell numbers of NR1 and NR2A.
Animal Model:22-month-old transgenic Tg2576 mice
Dosage:0.4-1 mg/mL
Administration:Intracerebroventricular injection (ICV), 20 min
Result:Decreased the number of amyloid plaque.Decreased the size of the remaining individual plaques.Reduced amyloid plaque burden.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备